The two questions that organize heart failure
Heart failure is the most common inpatient diagnosis over age 65 and carries roughly 50% mortality within five years of diagnosis. It is also the single largest Medicare hospitalization expenditure. The good news for clinicals is that the reasoning is unusually tidy: two questions sort almost every patient.
Systolic or diastolic?
Translation: what is the ejection fraction? HFrEF is a pump problem; HFpEF is a filling problem with a normal EF. Different drugs, different targets.
Wet or dry, warm or cold?
The four-quadrant bedside assessment. Wet + warm gets a diuretic. Cold + wet gets an inotrope. Getting this backwards harms the patient.
A normal lung exam does not exclude it
Rales can be absent in 80% of patients with chronically elevated filling pressures because of lymphatic compensation. Do not rule out heart failure on lung exam alone.
- > 6.5 million US adults affected; 650,000 new cases diagnosed each year
- Most common inpatient diagnosis over age 65
- 50% mortality within 5 years of diagnosis
- $30.7 billion per year — the single largest Medicare hospitalization expenditure
- Hospitalizations split roughly 53% HFrEF / 47% HFpEF. Black males have the highest HFrEF proportion (70%); Caucasian females the highest HFpEF (59%)
Two systems that answer different questions
The EF tells you the mechanism and therefore the drug. The NYHA class and ACC/AHA stage tell you where the patient is on the trajectory and therefore what is on the table.
By ejection fraction — the mechanistic split
| Type | EF | Mechanism | Structural signature |
|---|---|---|---|
| HFrEF — systolic failure | ≤ 40% | Impaired contractility → reduced stroke volume and cardiac output | Eccentric hypertrophy and chamber dilation. Concentric vs. eccentric is the fastest way to tell the two apart on imaging. |
| HFmrEF — midrange | 41–49% | Between the two; behaves more like HFrEF with respect to therapy decisions | Mixed. |
| HFpEF — preserved EF | ≥ 50% | Normal contractility but impaired ventricular filling (relaxation); nondilated LV with elevated LV filling pressures | Concentric hypertrophy. Cardiothoracic ratio < 55% on an AP chest film. |
By function — NYHA classification
| Class | Definition | What the patient tells you |
|---|---|---|
| I | No limitation of activity | "I can do everything I used to." Ordinary activity does not cause symptoms. |
| II | Slight limitation; comfortable at rest or with mild exertion | "I get winded on the stairs, but I am fine sitting." |
| III | Marked limitation; comfortable only at rest | "I can't do much of anything without stopping to catch my breath." |
| IV | Complete rest; any activity brings discomfort, symptoms at rest | "I am short of breath sitting still." |
By structure and progression — ACC/AHA stages
The stages are not interchangeable with NYHA class. A patient can be Stage C, NYHA I — structural disease with symptoms that are currently well controlled. The distinction is that stages are unidirectional and describe disease progression, while NYHA class describes current symptoms and can move in both directions.
| Stage | Definition | Goal and drugs |
|---|---|---|
| A | High risk, no structural disease — hypertension, CAD, diabetes, obesity, metabolic syndrome, cardiotoxin use, or family history of cardiomyopathy | Goal: heart-healthy lifestyle; prevent vascular/coronary disease and LV structural abnormality. Drugs: ACEI/ARB in appropriate patients; statins as appropriate. |
| B | Structural disease, no symptoms — previous MI; LV remodeling (LVH, low EF); asymptomatic valvular disease | Goal: prevent HF symptoms and further remodeling. Drugs: ACEI/ARB and β-blockers as appropriate; ICD in selected patients. |
| C | Structural disease with symptoms — known structural disease plus HF signs and symptoms | Goal: control symptoms, improve quality of life, prevent hospitalization and mortality. Routine drugs: diuretics for fluid retention, ACEI/ARB, ARNI, β-blockers, aldosterone antagonists. |
| D | Refractory HF — marked symptoms at rest; recurrent hospitalizations despite guideline-directed medical therapy | Options: heart transplant, chronic inotropes, temporary/permanent mechanical circulatory support, palliative care and hospice, ICD deactivation. |
An ICD prevents sudden death. In a patient dying of refractory pump failure, that can convert a comfortable death into a prolonged one. ICD deactivation is a legitimate, guideline-listed option in Stage D and belongs in the goals-of-care conversation — a detail that shows up in practice far more than on exams.
One most common cause, one leading acute risk
Coronary artery disease is the most common cause of chronic heart failure. Hypertension is the leading risk factor for acute heart failure. Keep those two straight — exams separate them deliberately.
Coronary artery disease
LV dysfunction from CAD is the most common cause of chronic HF. An MI with atherosclerotic CVD carries an 8–10× increased risk of subsequent heart failure through ventricular remodeling.
Hypertension
Risk is 3× higher in patients with hypertension — the leading risk factor for acute HF and the most common driver of decompensation you will actually see on the ward.
Everything else that adds load
Comorbid and lifestyle drivers
- Diabetes mellitus and metabolic syndrome
- Physical inactivity, obesity, smoking
- Excessive alcohol intake
- Thyroid disease
- Pregnancy
- Cardiomyopathy; valvular disease
Acute precipitants of decompensation
- Infection — a very common trigger
- Arrhythmia, especially new atrial fibrillation with rapid ventricular ' 'response
- Ischemia and acute MI
- Anemia; thyroid disease
- Cardiotoxic chemotherapy
- Medication non-adherence; dietary sodium indiscretion
When you are facing acute cardiogenic pulmonary edema, the single most common driver is ischemia — coronary artery disease with myocardial ischemia and infarction — aggravated by obesity, limited exercise, dyslipidemia, and cigarette smoking. Other drivers: arrhythmias (tachycardia especially, and bradycardia), hypertension, valvular dysfunction, thyroid dysfunction (hyper- or hypothyroidism), diabetes mellitus, viral myocarditis, idiopathic cardiomyopathy, renal failure, and drug therapy (especially certain chemotherapeutic agents).
Correcting the cause is the first principle of treatment — especially ischemia.
The four compensatory mechanisms that become the disease
These are worth understanding rather than memorizing, because they explain why the drug classes work. Every one of them helps briefly and then causes harm.
| Mechanism | What happens | Why it becomes maladaptive |
|---|---|---|
| Hypertrophy | The wall thickens with increased muscle mass | Higher myocardial oxygen demand — the thickened muscle needs more blood than the diseased coronaries can deliver. |
| Dilatation | Chambers enlarge; stretched fibers increase contractile force (Frank-Starling) | Works up to a point, then overstretching impairs actin–myosin interaction and contractile force falls. |
| Sympathetic nervous system | Inadequate CO releases epinephrine/norepinephrine → increased heart rate, increased SVR (afterload), increased myocardial oxygen demand | Raises afterload against a failing pump and increases oxygen demand — a direct route to ischemia and arrhythmia. |
| Renal (RAAS) | Decreased CO → renin → angiotensin I → angiotensin II (via ACE) → vasoconstriction + aldosterone → sodium retention → ADH → water retention | Vasoconstriction plus sodium and water retention increase preload and afterload. This is exactly why ACEI/ARB, β-blockers, and aldosterone blockade work. |
The difference between HFrEF and HFpEF therapy in one line
Prove mortality benefit with drugs
ACEI (or ARB/ARNI), β-blocker, aldosterone antagonist, and a diuretic for congestion. The pillars have mortality benefit and are titrated up.
Treat the pressure and the congestion
Control blood pressure to systolic < 130 mmHg, sodium restriction, diuretic for fluid overload, MRA, and a β-blocker if there is prior MI, hypertension, or atrial fibrillation. Avoid over-diuresis.
BNP is the money number — but never alone
The diagnosis is clinical first, supported by BNP and the echocardiogram. The echo is the study that changes management, because it gives you the EF.
What the patient reports
- Fatigue — may be an early sign; and dyspnea
- Orthopnea; paroxysmal nocturnal dyspnea or nocturnal cough, usually 1–3 hours after falling asleep
- Cough; tachycardia; edema of the legs, liver, spleen, abdomen, and lungs
- Nocturia — supine fluid shifts back into the intravascular space
- Weight gain of 1 kg = 1 L of fluid — the number that makes daily weights useful
Left-sided versus right-sided backup
| Left-sided failure — into the lungs | Right-sided failure — into the systemic veins |
|---|---|
| Rales; crackles and wheezes; dyspnea | Increased central venous pressure; JVD |
| Bilateral infiltrates on chest radiograph | Peripheral edema |
| S3 (ventricular gallop) common; rarely S4 | Hepatomegaly with hepatojugular reflux |
| Atrial fibrillation (atrial distention) | Ascites |
| Pulsus alternans — every other pulse beat diminished | S3 and/or S4 heart sounds |
| Increased pulmonary capillary wedge pressure; pulmonary edema | RV heaves; nocturia |
Rales can be absent in up to 80% of patients with chronically elevated filling pressures, because lymphatic drainage compensates over time. A clear chest does not mean a dry patient. Look at the neck veins, the weight trend, and the BNP instead.
BNP and NT-proBNP interpretation
| BNP (pg/mL) | Interpretation |
|---|---|
| > 500 | HF likely — positive predictive value 90% |
| < 100 | HF unlikely — negative predictive value 90% |
| 100–500 | Gray zone — consider PE, cor pulmonale, renal failure, and stable heart failure as alternative explanations |
- Age — mean BNP rises with age: 55–64 → 26 pg/mL; 65–74 → 31 pg/mL; ≥ 75 → 63 pg/mL
- Renal dysfunction — reduces clearance, falsely raising the level
- Sex — higher in women
- ARNI (sacubitril/valsartan) — affects BNP interpretation because ' 'sacubitril inhibits neprilysin, the enzyme that degrades natriuretic peptides. NT-proBNP is not affected the same way, which is why it is often preferred ' 'in patients on an ARNI
NT-proBNP normal values: < 125 pg/mL under age 75; < 450 pg/mL at 75 and over. It rises with age and renal dysfunction.
The rest of the workup
| Test | What you are looking for |
|---|---|
| Echocardiogram | The key study. EF, valvular function, wall motion (global and segmental), diastolic function, and right-heart pressures to detect pulmonary hypertension. |
| ECG | Prior MI, atrial fibrillation, LBBB, PVCs — and ischemia as a precipitant. |
| Chest radiograph | Cardiomegaly and congestion. In cardiogenic pulmonary edema look specifically for vascular redistribution to the upper lung fields, interstitial edema, Kerley B lines, pleural effusions (usually bilateral or on the right), and cardiomegaly. |
| Electrolytes, BUN/creatinine/GFR, glucose, lipids, LFTs, TSH | Renal function drives diuretic and ACEI/ARB dosing. Hyponatremia is a poor prognostic sign. Check magnesium too — it matters for arrhythmia risk. |
| CBC | Anemia — both a cause of decompensation and a reason for symptoms. |
| Cardiac enzymes | Especially if recent MI or unstable angina is suspected. |
| Pulmonary function studies | Not useful during acute pulmonary edema, but when stable they demonstrate a restrictive defect (reduced vital capacity) and evaluate coexisting COPD. |
Insertion is generally not necessary to treat heart failure. Consider it occasionally to document severity, especially with hypotension — the situation where aggressive fluid therapy could further aggravate CHF, so you need to know the filling pressures. A PA catheter can determine cardiac output, cardiac index, systemic vascular resistance, and pulmonary capillary wedge pressure.
Prefer less-invasive guidance: bedside ultrasound measurement of the inferior vena cava (IVC) plus clinical indicators of volume status. Routine PA catheterization is not recommended.
The Stage C HFrEF pillars, then the acute moves
Two separate jobs. Chronic therapy in Stage C HFrEF is about four pillars that reduce mortality. Acute decompensation is about deciding between a diuretic, a vasodilator, and an inotrope based on perfusion and congestion.
Chronic HFrEF — the guideline-directed pillars
| Pillar | Agents and doses | Pearls and contraindications |
|---|---|---|
| ACE inhibitor — or ARB | Captopril 6.25 mg TID → 50 mg TID · Enalapril 2.5 mg BID → 10–20 mg BID · Lisinopril 2.5–5 mg daily → 20–40 mg daily · Ramipril 1.25–2.5 → 10 mg daily | Start low, titrate. ↓ preload and afterload; ↓ mortality. Use an ARB if cough or angioedema with an ACEI. Monitor potassium and creatinine. |
| β-blocker | Carvedilol 3.125 mg BID → 50 mg BID · Bisoprolol 1.25 → 10 mg daily · Metoprolol succinate ER 12.5–25 → 200 mg daily | Recommended for all HFrEF — even with diabetes, COPD, or PVD. Slows progression; ↓ mortality. Caution with recurrent hypoglycemia, asthma, or resting limb ischemia. Only these three are the evidence-based choices. |
| Aldosterone antagonist (MRA) | Spironolactone 12.5–25 mg daily → 25 mg daily or BID · Eplerenone 25 mg daily → 50 mg daily | NYHA II–IV HFrEF to reduce morbidity and mortality. Requires K&sup+; < 5.0 mEq/L and adequate renal function: creatinine ≤ 2.5 (men) or ≤ 2.0 (women), or eGFR > 30 mL/min/1.73 m². Typical start spironolactone 12.5 mg or eplerenone 25 mg. |
| ARNI | Sacubitril/valsartan 49/51 mg BID → 97/103 mg BID; may start at 24/26 mg BID | Replaces an ACEI/ARB in NYHA II–III HFrEF who tolerate it. Never with an ACEI/ARB, or within 36 hours of an ACEI dose; never with a history of angioedema. |
The add-ons
Ivabradine
5 mg daily → 7.5 mg daily. Inhibits the If current in the SA node. Add for sinus rhythm with HR > 70 on maximum tolerated β-blocker, or when the patient cannot tolerate a β-blocker.
Hydralazine + isosorbide dinitrate
Fixed-dose combo 20/37.5 mg TID → 40/75 mg TID; or separate isosorbide 20–30 mg + hydralazine 25–50 mg TID. Standard add-on for African American patients with NYHA III–IV HFrEF, in addition to a β-blocker and ACEI.
Digoxin
0.125 mg daily in most patients (by lean body mass, renal function, and other drugs). Goal level 0.5–0.9 ng/mL. High doses (> 0.25 mg daily) are not recommended for rate control. Monitor digoxin and potassium closely — toxicity can occur even at "normal" levels, especially with hypokalemia.
Loop diuretics
Class of choice for congestion — loop, not thiazide, is usually necessary. After initial short-acting therapy, more frequent dosing (BID–TID) beats larger single doses. Oral torsemide for poor absorption or erratic effect, especially right-sided HF with refractory retention.
| Drug | Initial daily dose | Max daily | Duration of action |
|---|---|---|---|
| Bumetanide | 0.5–1 mg once or twice | 10 mg | 4–6 hr |
| Furosemide | 20–40 mg once or twice | 600 mg | 6–8 hr |
| Torsemide | 10–20 mg once | 200 mg | 12–16 hr |
| Chlorothiazide | 250–500 mg once or twice | 1,000 mg | 6–12 hr |
| Chlorthalidone | 12.5–25 mg once | 100 mg | 24–72 hr |
| Hydrochlorothiazide | 25 mg once or twice | 200 mg | 6–12 hr |
| Indapamide | 2.5 mg once | 5 mg | 36 hr |
| Metolazone | 2.5 mg once | 20 mg | 12–24 hr |
| Spironolactone | 12.5–25 mg once | 50 mg | 1–3 hr |
| Amiloride | 5 mg once | 20 mg | 24 hr |
| Triamterene | 50–75 mg twice | 200 mg | 7–9 hr |
Sequential nephron blockade
Add metolazone 2.5–10 mg once, or HCTZ 25–100 mg once/twice, or IV chlorothiazide 500–1,000 mg once to a loop diuretic for persistent retention. Avoid long-term daily use (especially metolazone) because of electrolyte shifts and volume disturbance.
NSAIDs, non-dihydropyridine calcium channel blockers (diltiazem, verapamil), thiazolidinediones, and most antiarrhythmics. Each either retains sodium and water, depresses contractility, or both.
Acute decompensated heart failure — the four-quadrant approach
Assess two things at the bedside: perfusion (warm or cold) and congestion (wet or dry).
| Profile | Findings | Treatment |
|---|---|---|
| Warm & wet | Preserved perfusion (warm extremities, adequate urine output, blood pressure acceptable) with congestion | IV loop diuretic FIRST + vasodilators (IV nitroglycerin) + oxygen/ventilatory support as needed. This is the most common presentation and the one tested most often. |
| Cold & wet | Hypoperfusion with congestion | Inotropes (dobutamine, milrinone, dopamine). Avoid vasodilators (nitrates, morphine). Start diuretics only after inotropes. |
| Warm & dry | Compensated — perfusion and volume both acceptable | Optimize oral guideline-directed medical therapy; no escalation needed. |
| Cold & dry | Hypoperfusion without congestion — hypovolemic or low-output | Careful volume assessment; this is where a fluid bolus may actually be appropriate. Never give a fluid bolus to a congested patient. |
Never give a fluid bolus to a congested ADHF patient. And avoid preload reduction if you suspect aortic stenosis, HOCM, or pulmonary hypertension — those patients are preload-dependent and will arrest.
Inpatient ADHF pearls
- Diagnose by signs and symptoms; use BNP when unsure, never in isolation
- Continue the home β-blocker unless the patient is hypotensive or bradycardic. If not already on one, hold until euvolemic and compensated
- No routine oxygen if not hypoxic. CPAP can reduce preload while diuretics work — and if the patient cannot sustain the work of breathing, CPAP first, then intubation if necessary
- IV nitroglycerin or nitroprusside plus diuretics for acute pulmonary edema or severe hypertension, if not hypotensive
- Avoid ACEI/ARB if hypotensive, in acute kidney injury, or with hyperkalemia
- Inotropes only with evidence of hypoperfusion (or known high filling pressures)
- VTE prophylaxis; ultrafiltration if diuretic-resistant; routine PA catheter not recommended
- Daily: weight (after the morning void), intake and output, orthostatic vital signs, K/Mg/Na, BUN/Cr, and examination for edema, JVD, and rales
Dobutamine
2.5–20 mcg/kg/min; increase or decrease by 1 mcg/kg/min at intervals no longer than every 30 minutes. Titration parameter: CO and CI. Adverse effects: arrhythmogenic, may potentiate hypokalemia, myocardial ischemia, hypotension/vasodilation.
Preferred vasoactive agent for cardiogenic shock with low output and increased afterload. Septic shock with myocardial dysfunction may require norepinephrine plus dobutamine. Higher doses may be required for patients previously on β-blockers.
Milrinone
Loading dose 50 mcg/kg over 10 minutes, followed by continuous infusion 0.125–0.75 mcg/kg/min; increase or decrease by a minimum of 0.125 mcg/kg/min at intervals no longer than every 6 hours. Titration parameter: CO and CI. Adverse effects: arrhythmogenic, thrombocytopenia, myocardial ischemia, hypotension/vasodilation.
The loading dose is frequently omitted. Reduce the dose in renal impairment. Requires slower titration than dobutamine.
Nitroglycerin and nitroprusside
Nitroglycerin reduces preload; nitroprusside reduces afterload. Sublingual or IV nitroglycerin; nitroglycerin patches such as Nitro-Dur 0.4 mg applied daily; oral long-acting nitrates such as isosorbide. Nitrates may or may not be appropriate depending on the cause — for example, arrhythmia or valvular heart disease changes the calculus. If the patient has chest pain, morphine may be used as well.
What to eliminate
Eliminate cardiac depressants: non-dihydropyridine calcium channel blockers (diltiazem, verapamil). Remove β-blockers for acute decompensation and resume when clinically stable.
Admit if
- Hypotension
- Worsening renal function
- Altered mental status
- Dyspnea at rest
- Hemodynamically significant arrhythmia, including new atrial fibrillation
- ACS
Consider admission for: weight gain of 5 kg or more, major electrolyte disturbances, or repeated ICD firings.
Devices
- ICD if EF ≤ 30% (or 31–35% with NYHA II–III, more than 40 days post-MI), or for secondary prevention
- CRT / biventricular pacing if sinus rhythm with LBBB ≥ 120–150 ms and EF ≤ 35%, NYHA II–III
- Stage D: transplant, LVAD, chronic inotropes, palliative care and hospice
Diet and lifestyle
< 4 g salt/day (lecture); 3 g sodium/day is often appropriate. Fluid restriction < 1.5–2 L if sodium is below 130 or in Stage D. Daily weights.
- Correct the cause of the CHF if known, especially ischemia.
- Oxygen usually via nasal cannula at low flow rates (2 L/min); in frank pulmonary edema give oxygen in higher amounts — use mask delivery as needed.
- If the patient cannot sustain the work of breathing during an acute episode, attempt noninvasive positive pressure ventilation via CPAP, followed by intubation and mechanical ventilation if necessary. This redistributes edema out of the lungs and back into the vascular space and offloads the work of breathing.
- Decrease afterload with an ACE inhibitor or ARB as blood pressure tolerates.
- Decrease preload with appropriate diuretics.
- Inotropic support in acute decompensation — dobutamine and milrinone. Inotropes should only be started when there is hypotension AND evidence of reduced organ perfusion, and in those cases dobutamine is usually first-line.
- β-adrenergic antagonists to help regulate catecholamines if blood pressure and heart rate will tolerate it.
- Aggressiveness must be proportionate to the severity of interstitial edema and respiratory distress.
Two flows: classify, then resuscitate
Algorithm 1 — New or suspected heart failure
HFpEF → BP to systolic < 130 mmHg, sodium restriction, diuretic for overload, MRA, β-blocker if prior MI/HTN/AFib. Avoid over-diuresis.
Algorithm 2 — Acute decompensation: the four quadrants
Congested but perfusing. Warm extremities, adequate urine output, ' acceptable blood pressure, with edema, JVD, orthopnea, or rales.
- IV loop diuretic first
- Vasodilator (IV nitroglycerin, or nitroprusside) if not hypotensive
- Oxygen only if hypoxic; CPAP if work of breathing is unsustainable
- Continue the home β-blocker unless hypotensive or bradycardic
Congested and hypoperfused. Cool extremities, oliguria, altered mentation, ' 'narrow pulse pressure, with congestion.
- Inotropes — dobutamine first-line, or milrinone
- Avoid vasodilators — no nitrates, no morphine
- Start diuretics only after inotropes
- Consider ICU-level monitoring; assess filling pressures
Flash edema with respiratory failure.
- Correct the cause — ischemia is the most common driver
- Oxygen; CPAP before intubation if the patient can cooperate
- IV nitroglycerin for preload reduction if not hypotensive
- IV loop diuretic
- Dobutamine or milrinone only if hypotensive with reduced organ perfusion
- Avoid preload reduction if aortic stenosis, HOCM, or pulmonary hypertension ' 'is suspected
Not congested. The reflex answer — more diuretic — is wrong ' 'here and causes harm.
- Warm & dry: optimize oral GDMT; no escalation
- Cold & dry: hypoperfusion without congestion — assess volume ' 'carefully; this is the rare patient who may need fluid
- Re-examine your diagnosis if the patient is not responding as expected
In warm & wet heart failure the diuretic comes first. In cold & wet the inotrope comes first and the diuretic waits. Giving a diuretic to a cold, hypoperfused patient worsens renal perfusion and can drop the blood pressure further. Giving a vasodilator to a cold patient does the same. The single most dangerous reflex in acute heart failure is more diuretic without checking perfusion.
Heart failure beside the other three
Heart failure keeps company with the other topics because CHF is a risk factor for pneumonia, a cause of sepsis mortality, and a source of the most common diagnostic confusion in a dyspneic patient.
Diuretic versus antibiotic — knowing which problem you are treating
| Topic | Primary lever | The overlap with heart failure |
|---|---|---|
| CHF | Volume and afterload. Diuretics, vasodilators, and neurohormonal blockade. | The disease itself. In HFrEF the pillars reduce mortality; in HFpEF you treat pressure and congestion. |
| Pneumonia | Antimicrobials plus support. | CHF is a comorbidity that drives pneumonia mortality, and pneumonia is a common precipitant of HF decompensation. A dyspneic febrile patient may have both — BNP helps separate cardiac from pulmonary etiology. |
| Sepsis | Early resuscitation, antibiotics, and source control. | Sepsis is a distributive shock state requiring 30 mL/kg of crystalloid — which a failing heart tolerates poorly. Tension between the two bundles is real; reassess frequently and use bedside ultrasound or IVC measurement. |
| UTI | Site-appropriate antibiotics; drainage if obstructed. | Urosepsis reached through the same distributive pathway. In a patient with CHF, avoid nephrotoxic agents and watch the fluid balance from both directions. |
Fluid: the same intervention, opposite indications
| Situation | Volume status goal | Why |
|---|---|---|
| Warm & wet CHF | Remove volume. IV loop diuretic first. | The patient is congested and perfusing. A fluid bolus here causes pulmonary edema. |
| Cold & wet CHF | Inotrope first, then diuresis. | Perfusion is the problem, not volume. Diuresing a hypoperfused patient worsens renal function and blood pressure. |
| Septic shock | Give volume. 30 mL/kg crystalloid for hypotension or lactate ≥ 4. | Distributive shock with relative hypovolemia from vasodilation and capillary leak. |
| Septic shock in a patient with CHF | Resuscitate, but reassess constantly. Escalate vasopressors earlier. | The failing ventricle tolerates a 30 mL/kg bolus poorly. Use bedside IVC assessment and smaller, reassessed boluses rather than a single large volume. |
| Cardiogenic pulmonary edema | Remove volume; reduce preload. | Except with aortic stenosis, HOCM, or pulmonary hypertension, where preload reduction is dangerous — those patients are preload-dependent. |
- Dyspneic patient with bilateral infiltrates and hypoxia — ' pneumonia, cardiogenic pulmonary edema, or ARDS? Fever and productive cough point to ' 'pneumonia; BNP < 100 pg/mL supports ARDS and makes cardiogenic edema ' 'unlikely; a high PCWP with a normal PAP means cardiogenic, while a normal PCWP with ' 'a high PAP means noncardiogenic (ARDS, sepsis).
- Pleural effusion in a patient with CHF — a transudate from CHF is ' 'managed with diuresis and serial chest radiographs, not thoracentesis, when ' 'the risk of infection is small. But always consider parapneumonic effusion ' 'and pulmonary embolism, which need different treatment entirely.
- Post-MI patient who becomes dyspneic — new heart failure from ' 'remodeling, pericarditis (in 10–15% within the first week), or a mechanical ' 'complication such as papillary muscle rupture. A new murmur after MI is a ' 'red flag for the last one.
The 14 facts to carry into clinicals
- CAD is the most common cause of chronic HF; hypertension is the leading risk factor for acute HF. Do not swap those two.
- EF defines the type: ≤ 40% HFrEF (systolic, eccentric hypertrophy); 41–49% HFmrEF; ≥ 50% HFpEF (diastolic, concentric hypertrophy, cardiothoracic ratio < 55% on AP film).
- NYHA is functional and reversible; ACC/AHA stages are structural and unidirectional. A patient can be Stage C, NYHA I.
- BNP > 500 = HF likely; < 100 = HF unlikely; 100–500 = gray zone — consider PE, cor pulmonale, renal failure, and stable HF.
- BNP rises with age and renal dysfunction and is higher in women. NT-proBNP normals are < 125 under age 75 and < 450 at 75 and over. ARNI treatment affects BNP interpretation.
- The four HFrEF pillars: ACEI/ARB/ARNI, β-blocker (carvedilol, bisoprolol, or metoprolol succinate only), aldosterone antagonist, and diuretic for congestion.
- ARNI never with an ACEI/ARB, and never within 36 hours of an ACEI dose; contraindicated with a history of angioedema.
- MRA requires K&sup+; < 5.0 and creatinine ≤ 2.5 (men) / ≤ 2.0 (women) or eGFR > 30. Check potassium and renal function at 3 days and 1 week, then at least monthly for the first 3 months.
- Avoid NSAIDs, non-DHP calcium channel blockers, thiazolidinediones, and most antiarrhythmics.
- Loop diuretics are the class of choice. More frequent dosing beats larger single doses. Sequential nephron blockade with metolazone for resistant congestion — short-term only.
- Warm & wet → IV loop diuretic first. Cold & wet → inotrope first, diuretic after.
- Never give a fluid bolus to a congested patient, and avoid preload reduction with aortic stenosis, HOCM, or pulmonary hypertension.
- Continue the home β-blocker during decompensation unless hypotensive or bradycardic; if the patient is not on one, hold until euvolemic and compensated.
- ICD if EF ≤ 30% (or 31–35% with NYHA II–III, more than 40 days post-MI). CRT if sinus with LBBB ≥ 120–150 ms and EF ≤ 35%, NYHA II–III.
- Diuresing a cold patient. Check perfusion before you reach for the furosemide.
- Trusting a normal BNP in isolation — especially in the gray zone, in renal failure, and in the elderly.
- Stopping a β-blocker reflexively because the patient is admitted with decompensation. Continue it unless there is hypotension or bradycardia.
Six questions, then reveal
Answer out loud before opening each one.
A 68-year-old man is admitted with 3 days of worsening dyspnea, orthopnea, and 4 kg weight gain. He is warm, his extremities are well perfused, urine output is adequate, and his blood pressure is 148/88 mmHg. He has bilateral rales and JVD. What is the first-line management?
IV loop diuretic first, plus a vasodilator if not hypotensive. This is the classic warm & wet profile: congested but adequately perfusing.
A fluid bolus would be dangerous — never give one to a congested patient. Inotropes are reserved for hypotension with evidence of reduced organ perfusion (cold & wet). Morphine and nitrates are avoided in cold & wet because the patient is already vasoconstricted and preload-dependent.
The same patient now has cool extremities, mottled skin, a urine output of 15 mL/hr, and a blood pressure of 84/56 mmHg — but he still has rales and JVD. What changes?
He is now cold & wet. The answer becomes inotropes — dobutamine first-line, or milrinone — and vasodilators are contraindicated, including nitrates and morphine. Start diuretics only after inotropes.
Dobutamine 2.5–20 mcg/kg/min is the preferred vasoactive agent for low output with increased afterload, and it is usually first-line when inotropes are indicated. Milrinone 0.125–0.75 mcg/kg/min (loading dose often omitted) requires dose reduction in renal impairment and titrates more slowly.
Which beta-blocker is appropriate for chronic HFrEF?
Carvedilol, bisoprolol, or metoprolol succinate ER. These three are the evidence-based choices and each reduces mortality.
Metoprolol tartrate is not interchangeable with the succinate ER formulation. And remember the broader point: β-blockers are recommended for all HFrEF — even with diabetes, COPD, or PVD. Caution applies with recurrent hypoglycemia, asthma, or resting limb ischemia.
A patient with HFrEF (EF 30%, NYHA III) is on an ACE inhibitor and a beta-blocker. Which addition is most likely to reduce mortality?
An aldosterone antagonist — spironolactone or eplerenone, for NYHA II–IV HFrEF to reduce morbidity and mortality.
Before you add it, confirm potassium < 5.0 mEq/L and adequate renal function: creatinine ≤ 2.5 (men) or ≤ 2.0 (women), or eGFR > 30 mL/min/1.73 m². Discontinue or reduce potassium supplements. Check potassium and renal function at 3 days and 1 week, then at least monthly for the first 3 months.
A patient with HFrEF is switched from lisinopril to sacubitril/valsartan. What must you verify?
That the ACE inhibitor was stopped at least 36 hours before the first ARNI dose — and that the patient has no history of angioedema.
ARNI replaces an ACEI/ARB in NYHA II–III HFrEF who tolerate it. It must never be given with an ACEI/ARB or within 36 hours of an ACEI dose because of the risk of angioedema. Also note the BNP interpretation caveat: sacubitril inhibits neprilysin, the enzyme that degrades natriuretic peptides, so BNP is affected but NT-proBNP is not.
A 74-year-old woman with known heart failure has a BNP of 340 pg/mL. Does she have decompensated heart failure?
You cannot tell from the number alone. 100–500 pg/mL is the gray zone. You must consider PE, cor pulmonale, renal failure, and stable chronic heart failure as alternative explanations — and interpret the value against her baseline and her examination.
Above 500 makes HF likely (PPV 90%); below 100 makes it unlikely (NPV 90%). Remember what else moves the number: age (mean BNP rises from 26 pg/mL at 55–64 to 63 pg/mL at 75 and over), renal dysfunction, female sex, and ARNI therapy. BNP supports a clinical diagnosis; it never makes one by itself.
Sources
Every clinical statement on this page traces to one of the sources below. Course readings are cited by chapter so you can find the original; guidelines are cited by year and issuing body so you can check whether a newer version has appeared.
Fletcher, & colleagues (2021). Heart failure (Chapter 18). In Practice considerations for adult-gerontology acute care nurse practitioners (3rd ed.). The primary assigned reading. Source of the HF definition and epidemiology (> 6.5 million adults, 650,000 new cases/year, 50% five-year mortality, $30.7 billion/year), the HFrEF/HFmrEF/HFpEF EF cutoffs and hypertrophy patterns, NYHA classes, ACC/AHA stages, CAD and hypertension as cause and risk factor, the four compensatory mechanisms, left-versus-right examination findings, BNP thresholds and age-related means, and every drug dose on this page including Table 18.3 (the Stage C HFrEF ladder), Table 18.4 (MRA hyperkalemia minimization), and Table 18.5 (oral diuretics).
Chapter 27 — Restrictive (inflammatory) lung diseases and congestive heart failure/pulmonary edema. Source of the cardiogenic pulmonary edema content: ischemia as the most common driver, the etiology list, the progression from exertional dyspnea to orthopnea to paroxysmal nocturnal dyspnea, the chest radiograph findings (vascular redistribution, interstitial edema, Kerley B lines, pleural effusions, cardiomegaly), the diagnostic workup, and the acute treatment discussion including CPAP, nitrates, morphine, inotrope selection, and the PA catheter caveat.
Chapter 22–23 (oxygenation and ventilation measures). Context for the PCWP-versus-PAP distinction used in the cross-topic comparison: cardiogenic edema = high PCWP with normal PAP; noncardiogenic (pulmogenic) edema = normal PCWP with high PAP (ARDS, sepsis).
Chapter 29 (chest wall and secondary pleural disorders). Source of the Light's criteria framework and the rule that a transudate likely due to CHF is managed with diuresis and serial chest radiographs, whereas an exudate requires thoracentesis and fluid analysis.
Chapter 76 (management of the patient in shock). Source of the cardiogenic shock material: CI < 1.8 L/min/m² suggesting cardiogenic shock, EF < 30% on echocardiogram, the dobutamine and milrinone dose ranges and titration parameters, and the caution that norepinephrine requires slow titration in left ventricular depression.
N5301 Weeks 1–2 study guide and lecture slides — Heart failure section. Source of the ADHF four-quadrant teaching approach (warm/cold × wet/dry), the rule to never give a fluid bolus to a congested patient, the admonition to avoid preload reduction with aortic stenosis, HOCM, or pulmonary hypertension, the instruction to continue the home β-blocker during decompensation, and the device thresholds (ICD at EF ≤ 30%; CRT with LBBB ≥ 120–150 ms and EF ≤ 35%).
American College of Cardiology / American Heart Association / Heart Failure Society of America. Guideline for the management of heart failure (2022) and its focused updates. The current authority behind the four-pillar framework, the ARNI 36-hour rule, MRA eligibility criteria, and device indications. Confirm the latest version and any focused update before applying clinically.
Open the sources yourself
Direct links, so you can read the guideline rather than take my word for it. Open access means the full text is free; opens in browser means the publisher blocks automated checks but the page loads normally for you.
Guidelines and primary sources for this topic
Shared reference pages
This is a study aid built from course readings and published guidelines, not a standing order set. Doses are the ones those sources print — but your patient's renal function, weight, allergies, pregnancy status, and your institution's antibiogram and formulary decide what is actually given. Confirm every drug against your facility's policy and a current reference, and escalate to your preceptor rather than extrapolating from a study page.